Hdl Elevation
Hdl Elevation - Related Videos
08:24
Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation
0 Views •
Cited by 4 •
2017
Simple homogenization was used to prepare novel, high-density, lipoprotein-mimicking nanoparticles to encapsulate nerve growth factor. Challenges, detailed protocols for nanoparticle preparation, in vitro characterization, and in vivo studies are described in this article.
03:12
Freezing Point Depression and Boiling Point Elevation
0 Views •
2020
Boiling Point Elevation The boiling point of a liquid is the temperature at which its vapor pressure is equal to ambient atmospheric pressure. Since the vapor pressure of a solution is lowered due to the presence of nonvolatile solutes, it stands to reason that the solution’s boiling point will subsequently be increased. Vapor pressure increases with temperature, and so a solution will require a higher temperature than will pure solvent to achieve any given vapor pressure, including one...
09:09
Elevated Plus Maze for Mice
0 Views •
Cited by 533 •
2008
The elevated plus maze test is one of the most widely used tests for measuring anxiety-like behavior in mice. Here, we present a movie showing the detailed procedures for conducting the test.
03:04
Induction of Elevated Intraocular Pressure in a Rat Model
0 Views •
2025
Source: Lani-Louzada, R., et al., Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents. J. Vis. Exp. (2022)This video demonstrates the induction and monitoring of elevated intraocular pressure (IOP) in a rat model. The process involves cauterizing the limbal blood vessels, resulting in vessel occlusion and elevated IOP. The rat is then allowed to recover, and IOP is regularly monitored in both the experimental and control eyes for comparison.
09:03
Trabecular Meshwork Response to Pressure Elevation in the Living Human Eye
0 Views •
Cited by 7 •
2015
Trabecular meshwork (TM) migration into Schlemm’s canal space can be induced by acute pressure elevation by ophthalmodynamometer, and observed by spectral domain optical coherence tomography. The goal of this method is to quantify the morphometric response of the living outflow tract to acute pressure elevation in living tissues in situ.
FAQs
Therapies may increase HDL by stimulating apolipoprotein production, promoting the formation of HDL particles, or reducing the breakdown and clearance of HDL components. These routes can alter HDL concentration through different effects on particle availability and persistence in the blood. Distinguishing the mechanism helps researchers determine whether a candidate drug changes cholesterol handling in a meaningful way.
The same increase in measured HDL cholesterol may arise from increased production, enhanced particle formation, or slower component clearance. These mechanisms do not necessarily provide identical information about lipid metabolism or cholesterol transport. Pharmacological evaluation therefore examines how the change occurs, rather than treating the numerical rise alone as evidence of therapeutic benefit.
A higher HDL concentration indicates that the amount of measured HDL cholesterol has changed, but it does not establish cardiovascular benefit. Researchers also need to consider particle function, cholesterol transport, lipid metabolism, and relevant clinical outcomes. This distinction prevents a laboratory change from being interpreted as proof that a therapy improves cardiovascular health.
Researchers can compare the measured HDL increase with evidence of altered cholesterol transport and lipid metabolism. This approach asks whether the treatment affects the handling of cholesterol, rather than simply changing the concentration recorded in blood. Including cardiovascular biomarkers and, when available, clinical outcomes provides additional context for interpreting the pharmacological effect.
Assessment can include HDL concentration, indicators of cholesterol transport, measures related to lipid metabolism, and cardiovascular biomarkers. Researchers should also examine HDL particle function because concentration does not fully describe biological activity. When treatment evaluation permits, clinical outcomes add the most direct context for judging whether the observed pharmacological changes are beneficial.
Pharmacologists study this target when testing drugs or experimental therapies intended to modify cholesterol handling. The evaluation can determine whether a candidate changes apolipoprotein production, HDL particle formation, or component clearance, then relate those effects to lipid metabolism and cardiovascular biomarkers. The broader goal is to distinguish biochemical alteration from meaningful cardiovascular benefit.